Immunotherapy of metastatic renal cell carcinoma

Cancer Journal

Volumn 14, Issue 5, 2008, Pages 320-324

  McDermott, David F ^a,b   Atkins, Michael B ^a  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Immunotherapy; Interferon ; Interleukin 2; Renal cancer

Indexed keywords

ALPHA INTERFERON; AP 12009; BEVACIZUMAB; BMS 66513; CARBONATE DEHYDRATASE IX; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GC 1008; HYB 2055; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; MDX 1106; MEDROXYPROGESTERONE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; SORAFENIB; SUNITINIB; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 55349146633     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31818675c4     Document Type: Article

References (61)

1. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998;338:1265-1271.
2. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63:128-131.
3. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 1992;148:1247-1248.
4. Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother. 2002;51:637-644.
5. Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003;21:884-890.
6. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. Br J Urol. 2007;99:1282-1288.
7. Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001;19:141-147.
8. Lesimple T, Moison A, Guille F, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother. 2000;23:675-679.
9. Schwabb T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol. 2000;163:1322-1327.
10. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
11. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J Sci Am. 2002;8:2-11.
12. Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002;20:2017-2024.
13. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastatses and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169-1188.
14. Mule JJ, Yang JC, Lafreniere RL, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987;139:285-194.
15. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinorna. N Engl J Med. 2007;356:125-134.
16. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;356:115-124.
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinorna. New Engl J Med. 2007;356: 2271-2281.
18. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet. 2007;370:2103-2111.
19. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
20. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55-S57.
21. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Identification of the antigens mediating response. Ann Surg. 1998;228:307-319.
22. Belldegrun A, Webb DE, Austin HA III, et al. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol. 1989;141:499-503.
23. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486-498.
24. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer. 1986;57:1696-1699.
25. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987;14:36-42.
26. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5592.
27. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987;5:286-291.
28. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000;18:4009-4015.
29. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council and Collaborators. Lancet. 1999;353:14-17.
30. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
31. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005(1):CD001425.
32. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278.
33. Yang JC, Sherry RM, Stienberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
34. McDermott DF, Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
35. Negrier S, Perol D, Ravaud C, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer. 2007;110:2468-2477.
36. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
37. Motzer RJ, Bacil J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381.
38. Upton MP, Parker RA, Youmans A, et al. Renal cell carcinoma: histologic predictors of cytokine response. J Immunother. 2005;28:488-495.
39. Grabmaier K, A de Weijert MC, Verhaegh GW, et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004;23:5624-5631.
40. Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
41. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721.
42. Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2005;4:535.
43. Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006;106:566-575.
44. Schwarzberg T, Regan MM, Liu V, et al. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy. J Clin Oncol. 2008 (May 20 suppl; abstr 5044).
45. Ernstoff M, Regan MM, McDermott DF, et al. First-line therapy with bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients. J Clin Oncol. 2007 (June 20 suppl; abstr 15524).
46. Gollob JA, Ratnmell WK, Richmond T, et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-alpha2b) as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295.
47. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib plus interferon alpha2b (IFN) as first-line therapy for advanced renal cell carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007; 25:3296-3301.
48. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium. 2008; abstr 350.
49. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendretic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30:749-761.
50. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002;25:500-508.
51. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66:5910-5918.
52. Yang JC, Hughes M, Kammula U, et al. Impilimumab (anti-CLTA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830.
53. Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. 2008; 26: (May 20 suppl; abstr 3006).
54. Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: a human anti-transforiming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. J Clin Oncol. 2008;26: (May 20 suppl; abstr 9028).
55. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. J Clin Oncol. 2008;26: (May 20 suppl; abstr 3007).
56. Schmidt H, Selby P, Mouritzen U, et al. Subcutaneous dosing of recombinant human interleukin-21 is safe and has clinical activity: results from a dose-escalation study in stage 4 melanoma and renal cell cancer. J Clin Oncol. 2008;26: (May 20 suppl; abstr 3041).
57. Moore DJ, Hwang J, McGreivy J, et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol. 2005;23: (June 1 suppl; abstr 2503).
58. Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alfa-2a. Proc Am Soc Clin Oncol. 1992;11:202.
59. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 in patients with high-risk renal cell carcinoma-a cytokine working group phase III trial. J Clin Oncol. 2003;21:3133.
60. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004;90:985-990.
61. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995-3002.